A MULTIPARAMETER APPROACH TO CELL CYCLE ANALYSIS AS A STANDARD TOOL IN ONCOLOGY DRUG DISCOVERY - Flow Cytometry in Drug Discovery and Development - page 116

18. Traganos F, Juan G, Darzynkiewicz Z. Cell-cycle analysis of drug-treated cells. Methods
Mol. Biol. 2001;95:229-240.
19. Wang ZQ, Dudhane A, Orlikowsky T, Clarke K, Li X, Darzynkiewicz Z, Hoffmann MK.
CD4 engagement induces Fas antigen-dependent apoptosis of T cells in vivo. Eur. J.
Immunol. 1994;24(7):1549-1552.
20. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis.
Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using
fluorescein labeled annexin V. J. Immunol. Methods 1995;184(1):39-51.
21. Mohr A, Liu J, Meyer LH, Karawajew L, Debatin KM. Identification of deficient
mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric
analysis of intracellular cytochrome c, caspase-3 and apoptosis. Apoptosis 2004;9
(4):457-465.
22. Promega CorporationAnti-PARP p85 fragment pAb Technical bulletin #TB273. Available
at www.promega.com.
23. Darzynkiewicz Z, Galkowski D, Zhao H. Analysis of apoptosis by cytometry using
TUNEL assay. Methods 2008;44(3):250-254.
24. Gorczyca W, Melamed MR, Darzynkiewicz Z. Analysis of apoptosis by flow cytometry.
Methods Mol. Biol. 1998;91:217-238.
25. Darzynkiewicz Z, Bedner E, Traganos F. Difficulties and pitfalls in analysis of apoptosis.
Methods Cell Biol. 2001;63:527-546.
26. O Leary J, Muggia FM. Camptothecins: a review of their development and schedules of
administration. Eur. J. Cancer 1998;34:1500-1508.
27. VanMaanen JMS, Retel J, De Vries J, Pinedo HM. Mechanism of action of antitumor drug
etoposide: a review. J. Natl. Cancer Inst. 1988;80:1526-1533.
28. O Dwyer PJ, AlonsoMT, Leyland-Jones B, Marsoni S. Teniposide: a review of 12 years of
experience. Cancer Treat. Rep. 1984;68(12):1455-1466.
29. Long BH. Mechanisms of action of teniposide (VM-26) and comparison with etoposide
(VP-16). Semin. Oncol. 1992; 19 (2 Suppl. 6): 3-19.
30. Long BH, Rose WC, Vyas DM, Matson JA, Forenza S. Discovery of antitumor
indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Curr. Med.
Chem. Anticancer Agents 2002;2:1-10.
31. Saulnier MG, Long BH, Frennesson DB, Ruediger E, Zimmermann K, Eummer JT, St.
Laurent DR, StoffanKM, B. NaiduN,MahlerM, Beaulieu F, BachandC, Lee FY, Fairchild
CR, Linda K. Stadnick LK, William C, Rose WC, Solomon C, Wong H, Martel A, Vyas
DM, Kramer R, Langley DR, Balasubramanian BN. Discovery of clinical candidate BMS-
250749 with broad spectrum antitumor activity in preclinical tumor models superior to the
marketed oncology drug, CPT-11. J. Med. Chem. 2005;48(7):2258-2261.
32. Raventos-Suarez C, Class K, Wild R, Menendez A, Long B. In vitro specificity profiling of
cellular topoisomerase activities using FACS analyses. 2004 ISAC XXII International
Congress on Analytical Cytology, Montpellier, France, May 22-27; 2004, Abstract 96207,
p. 115.
33. Raventos-Suarez C, Class K, Buczek JL, Balasubramanian N, Long B, Menendez AT.
Topoisomerase I is the target responsible for cytotoxicity of BMS-250749: confirmation by
flow cytometry. 92nd Annual Meeting, Proceedings of the American Association for
Cancer Research, NewOrleans, Mar 24-28, 2001(Abstract 562); Proc. Am. Assoc. Cancer
Res. 2001;42:103.